Trial Information

Summary: PHII-87 NCI #7703: Phase I/II Study of a Combination of Suberolyanilde Hydroxyamic Acid (Vorinostat) Plus Paclitaxel and Bevacizumab in Patients with Advanced Metastatic and/or Local Chest Wall Recurrent Breast Cancer

You have been asked to participate in this research study because you have stage IV breast cancer (cancer that has spread to other area(s) of your body).  The purpose of the phase I portion of this study is to determine a safe dose of vorinostat that may be used in combination with paclitaxel plus bevacizumab (standard treatment for stage IV breast cancer).  The purpose of the phase II portion of this study is to determine the effects of the combination of vorinostat and paclitaxel and bevacizumab on tumor shrinking or stabilizing (staying the same) and length of life and to evaluate the side effects of treatment.  Researchers will also take tumor and blood specimens to measure substances in the blood and tissue that may explain how the drugs affect cancer cells, give us a measure of how effective they may be, and identify characteristics of tumors that may help predict who is most likely to respond to this treatment.  Your treatment on this study is expected to last for as long as your cancer is not growing and you are not having any unmanageable side effects. After your treatment on this study is over, your medical condition will be followed indefinitely.

Patient Inclusion/Exclusion Criteria:

- See http://clinicaltrials.coh.org for additional information.

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: June 2, 2008 at 2:51:06 PM